CD39: the potential target in small cell lung cancer

Area of Science:

• Oncology
• Immunology

Background:

• Small cell lung cancer (SCLC) has a narrow treatment window, necessitating identification of novel therapeutic targets.
• CD39 is implicated in inhibiting natural killer (NK) cells and promoting tumor progression and metastasis.
• The role of CD39 in SCLC remains underexplored, prompting investigation into its associations with other surface antigens and patient survival.

Purpose of the Study:

• To investigate the correlation between CD39 expression and other surface antigens in SCLC.
• To determine the association between CD39 expression and survival outcomes in SCLC patients.

Main Methods:

• Immunohistochemistry (IHC) was performed on 75 SCLC patient samples.
• Receiver Operating Characteristic (ROC) curve analysis was used to determine cutoff values for CD39 and other antigens.
• Statistical analyses included Chi-square test, Kendall's tau-b correlation, logistic regression, Kaplan-Meier, and Cox regression analyses.

Main Results:

• 61.33% of SCLC patients expressed CD39.
• CD39 showed significant correlations with programmed cell death-ligand 1 (PD-L1), CD3, CD4, CD8, and forkhead box P3 (FOXP3) on tumor-infiltrating lymphocytes (TILs).
• Positive CD39 expression was associated with shorter relapse-free survival (RFS) (P=0.0390). High CD39 and low PD-L1 predicted poor prognosis (P<0.001).

Conclusions:

• CD39, PD-1, and PD-L1 are expressed on TILs in SCLC.
• CD39 expression is significantly associated with PD-L1, CD3, CD4, CD8, and FOXP3 on TILs.
• Positive CD39 expression predicts a poor prognosis, while low CD39 combined with high PD-L1 or immune cell markers suggests a more favorable prognosis.